Literature DB >> 10906870

Cementless acetabular replacement in the young. A 5- to 10-year prospective study.

A B Dunkley1, J D Eldridge, M B Lee, E J Smith, I D Learmonth.   

Abstract

This article presents a prospective clinical and radiologic review of 55 total hip replacements in 50 patients in which the cementless Harris-Galante porous-coated acetabular component was used. All patients were 50 years of age or younger. The cups were inserted by 15 different surgeons. The minimum followup was 5 years, with a mean of 7 years. No acetabular component has been revised for loosening, and none have migrated. Three (5.5%) cups have progressive bone-component radiolucent lines, two (3.6%) of which are complete. Six (10.9%) acetabular liners have been replaced for excessive polyethylene wear, and an additional four (7.3%) show sufficient wear to produce obvious radiographic eccentricity of the femoral head. All of the revised liners had 32-mm femoral heads and an initial polyethylene thickness of less than 6 mm. Although the results reflect excellent fixation of this component in the medium term, the incidence of exchange of the polyethylene liner for excessive wear is unacceptably high. The reduction in polyethylene thickness associated with the use of a metal-backed component and a 32-mm articulation was one of the factors contributing to the accelerated wear patterns seen in this series.

Entities:  

Mesh:

Year:  2000        PMID: 10906870     DOI: 10.1097/00003086-200007000-00021

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  2 in total

1.  THA with highly cross-linked polyethylene in patients 50 years or younger.

Authors:  Derek S Shia; John C Clohisy; Mark F Schinsky; John M Martell; William J Maloney
Journal:  Clin Orthop Relat Res       Date:  2009-01-14       Impact factor: 4.176

2.  Clinical and radiological results of hydroxyapatite-coated acetabular cups.

Authors:  J Blacha; J Gagała
Journal:  Int Orthop       Date:  2004-08-14       Impact factor: 3.075

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.